Clinical and Functional Evidence for the Pathogenicity of the LRRK2 P.arg1067gln Variant
Ai Huey Tan,Shen-Yang Lim,Tzi Shin Toh,Jia Wei Hor,Jia Lun Lim,Lei Cheng Lit,Azlina Ahmad-Annuar,Yi Wen Tay,Jia Nee Foo,Ebonne Ng,Kalai Arasu Muthusamy,Norlinah Mohamed Ibrahim,Khairul Azmi Ibrahim,Louis CS Tan,Jannah Zulkefli,Anis Nadhirah Khairul Anuar,Kirsten Black,Pawel Lis,Fei Xie,Zhidong Cen,Kai Shi Lim,Katja Lohmann,Shalini Padmanabhan,Dario Alessi,Wei Luo,Eng-King Tan,Esther Sammler
DOI: https://doi.org/10.21203/rs.3.rs-4920792/v1
2024-01-01
Abstract:LRRK2-related Parkinson’s disease (LRRK2-PD) is the most frequent form of monogenic PD worldwide, with important therapeutic opportunities, exemplified by the advancement in LRRK2 kinase inhibition studies/trials. However, many LRRK2 variants, especially those found in underrepresented populations, remain classified as variants of uncertain significance (VUS). Leveraging on Malaysian, Singaporean, and mainland Chinese PD datasets (n=4,901), we describe 12 Chinese-ancestry patients harbouring the LRRK2 p.Arg1067Gln variant, more than doubling the number of previously reported cases (total n=23, 87% East Asian, mean age of onset:53.9years). We determine that this variant is enriched in East Asian PD patients compared to population controls (OR=8.0, 95%CI:3.0-20.9), and provide supportive data for its co-segregation with PD, albeit with incomplete penetrance. Utilizing established experimental workflows, this variant showed increased LRRK2 kinase activity, by ~2-fold compared to wildtype and higher than the European p.Gly2019Ser variant. Taken together, p.Arg1067Gln should be reclassified from a VUS to pathogenic for causing LRRK2-PD.